| 000 | 01894 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250513111614.0 | ||
| 264 | 0 | _c19970227 | |
| 008 | 199702s 0 0 eng d | ||
| 022 | _a0735-1097 | ||
| 024 | 7 |
_a10.1016/s0735-1097(96)00492-5 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTardiff, B E | |
| 245 | 0 | 0 |
_aCoronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. _h[electronic resource] |
| 260 |
_bJournal of the American College of Cardiology _cFeb 1997 |
||
| 300 |
_a240-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aCoronary Angiography |
| 650 | 0 | 4 | _aCoronary Artery Bypass |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFibrinolytic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aHeparin _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMultivariate Analysis |
| 650 | 0 | 4 |
_aMyocardial Infarction _xdrug therapy |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 |
_aStreptokinase _xtherapeutic use |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aThrombolytic Therapy |
| 650 | 0 | 4 |
_aTissue Plasminogen Activator _xtherapeutic use |
| 700 | 1 | _aCaliff, R M | |
| 700 | 1 | _aMorris, D | |
| 700 | 1 | _aBates, E | |
| 700 | 1 | _aWoodlief, L H | |
| 700 | 1 | _aLee, K L | |
| 700 | 1 | _aGreen, C | |
| 700 | 1 | _aRutsch, W | |
| 700 | 1 | _aBetriu, A | |
| 700 | 1 | _aAylward, P E | |
| 700 | 1 | _aTopol, E J | |
| 773 | 0 |
_tJournal of the American College of Cardiology _gvol. 29 _gno. 2 _gp. 240-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0735-1097(96)00492-5 _zAvailable from publisher's website |
| 999 |
_c9005648 _d9005648 |
||